Joel Neal Maslow MD PhD MBA FACP
HIV/AIDS Medicine, Mycobacterial Disease
Chief, Division of Infectious Diseases
Join to View Full Profile
1040 Dekalb PikeSuite 200Blue Bell, PA 19422
Dr. Maslow is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Boston University Medical CenterFellowship, Infectious Disease, 1988 - 1991
Abington Memorial HospitalResidency, Internal Medicine, 1985 - 1988
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHInternship, Internal Medicine, 1984 - 1985- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1984
Certifications & Licensure
NJ State Medical License 2012 - 2025
PA State Medical License 1985 - 2022
MI State Medical License 2011 - 2013
MA State Medical License 1988 - 1999
American Board of Internal Medicine Internal Medicine
Clinical Trials
- GLS-5700 in Dengue Virus-Naïve Adults
- Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers Start of enrollment: 2018 Aug 28
Publications & Presentations
PubMed
- 2 citationsImmune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost.Woo Joo Kim, Christine C Roberts, Joon Young Song, Jin Gu Yoon, Hye Seong
Vaccine. 2023-06-29 - 8 citationsDNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond.Joel N Maslow, Ijoo Kwon, Sagar B Kudchodkar, Deborah Kane, Amha Tadesse
Vaccines. 2023-05-23 - 5 citationsSafety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction device.Woo Joo Kim, Christine C Roberts, Joon Young Song, Jin Gu Yoon, Hye Seong
International Journal of Infectious Diseases. 2023-03-01
Press Mentions
GeneOne Life Science to Begin Phase 2 Clinical Trial of COVID-19 Pill in KoreaSeptember 9th, 2021
Letter from the EditorOctober 23rd, 2019
Tolerability of Intramuscular and Intradermal Delivery by CELLECTRA® Adaptive Constant Current Electroporation Device in Healthy VolunteersJune 4th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
